Hutchmed has concluded enrolment of its multi-centre Phase II trial of fanregratinib (HMPL-453), a treatment for intrahepatic ...

FGFR2 fusion occurs in 10-15% of IHCC patients ... (“IHCC”) patients with fibroblast growth factor receptor (“FGFR”)2 fusion/rearrangement. The study is a single-arm, multi-center, open ...

Hutchmed (HCM) announced that it has completed enrollment of its a Phase II trial of fanregratinib for intrahepatic cholangiocarcinoma patients ...

The research delves into how mutations in FGFR2 and FGFR3 affect mandibular ... Gain-of-function mutations in fibroblast growth factor receptor (FGFR) genes are known to cause a range of skeletal ...

Hutchmed completes enrollment in phase II registration study of fanregratinib for intrahepatic cholangiocarcinoma in China: Hong Kong, Shanghai Saturday, March 8, 2025, 15:00 Hrs ...

The company’s lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients ...

Relay Therapeutics (NASDAQ:RLAY – Free Report) had its price objective lowered by The Goldman Sachs Group from $20.00 to $18.00 in a research report released on Thursday,Benzinga reports. The Goldman ...

BALVERSA (erdafitinib) has strong market potential in the FGFR-altered urothelial carcinoma space, particularly as a targeted therapy for patients wi ...

Eisai has filed for approval in Japan for tasurgratinib, its small-molecule fibroblast growth factor (FGF) receptor inhibitor, as a treatment for biliary tract cancers with FGFR2 gene fusion ...